-
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
•
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China, has announced that it has received approval from the US Food and Drug Administration (FDA) to commence a Phase II clinical study for its RIPK2 inhibitor, AC-101, in the treatment of ulcerative colitis (UC). Design…
-
Accropeutics Receives HREC Approval for AC-201 Phase I Trial
•
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the Australian Human Research Ethics Committee (HREC) to initiate a Phase I trial for its TYK2/JAK1 inhibitor pipeline candidate, AC-201. The study, which is randomized, double-blind, placebo-controlled, and involves single and multiple ascending doses, aims to…
